Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company, announced that its Compensation Committee has granted options to six new employees to purchase a total of 25,200 shares of common stock at $13.84 per share, the closing price on July 8, 2024. Additionally, 12,600 restricted stock units were awarded. These grants were made under the company's 2020 Inducement Plan, approved by the Board of Directors as per NYSE Rule 303A.08.
Arcus Biosciences and Taiho Pharmaceutical announced that Taiho has exercised its option for an exclusive license to quemliclustat in Japan and certain other Asian territories, excluding mainland China. This action is part of a 2017 agreement, marking the fourth option Taiho has exercised in Arcus's projects. Taiho will make a payment for this option and additional payments upon reaching certain milestones. Quemliclustat is an investigational CD73 inhibitor, and Arcus plans to begin a Phase 3 trial (PRISM-1) in 2024 for treating metastatic pancreatic ductal adenocarcinoma. This decision follows promising survival data from a Phase 1b study presented at the ASCO GI Cancers Symposium. Taiho will also support and manage the PRISM-1 study in Japan.
Arcus Biosciences announces the grant of employment inducement awards to two new employees. The grants include options to purchase a total of 3,500 shares of common stock at an exercise price of $16.41 per share, the closing price on June 24, 2024, and restricted stock units for 1,750 shares. These awards are given under the 2020 Inducement Plan, approved in January 2020 under the NYSE Listed Company Manual Rule 303A.08, aimed at incentivizing new talent.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced that its Compensation Committee has granted new employment inducement awards. These awards include options to purchase 36,100 shares of common stock at $16.09 per share, the closing price on June 10, 2024, and restricted stock units for 18,050 shares. The grants were made under the 2020 Inducement Plan, approved in January 2020, following NYSE rules.
Arcus Biosciences (NYSE:RCUS) has completed patient enrollment for its Phase 3 STAR-221 trial. This trial evaluates the combination of domvanalimab, an anti-TIGIT antibody, with zimberelimab and chemotherapy for treating advanced metastatic upper gastrointestinal (GI) adenocarcinomas. The significance of this trial lies in its potential to introduce the first anti-TIGIT antibody treatment to the market for this patient demographic. Earlier Phase 2 EDGE-Gastric study results showed promising efficacy, with a median progression-free survival (PFS) of 12.9 months and nearly 60% achieving PFS at 12 months without unexpected safety issues. The readout for the Phase 3 trial is anticipated soon.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in innovative cancer treatments, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event, set to take place in Miami Beach, FL, will feature a fireside chat with Arcus' management team on June 12th, 2024, at 10:00am ET. A live webcast of the discussion will be accessible via the 'Investors & Media' section of the company's website, with a replay available post-event.
Gilead Sciences and Arcus Biosciences announced significant findings from Cohort B of the ARC-9 study. The combination of etrumadenant and zimberelimab with FOLFOX chemotherapy and bevacizumab (EZFB) demonstrated a 63% reduction in the risk of death and a 73% reduction in disease progression compared to regorafenib in third-line metastatic colorectal cancer (mCRC) patients. The data showed a median overall survival of 19.7 months for EZFB, compared to 9.5 months for regorafenib. The findings will be presented at the 2024 ASCO Annual Meeting. The trial included 112 patients and showed a favorable safety profile for the EZFB regimen.
Gilead Sciences and Arcus Biosciences have announced significant results from Cohort B of the ARC-9 Phase 1b/2 study. The study tested a combination regimen including etrumadenant, zimberelimab, FOLFOX chemotherapy, and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC) patients. The EZFB regimen reduced the risk of death by 63% and disease progression by 73% compared to regorafenib. Median overall survival was 19.7 months for EZFB versus 9.5 months for regorafenib. Additionally, the EZFB regimen had a favorable safety profile with fewer treatment-emergent adverse events leading to discontinuation compared to regorafenib. These findings were presented at the ASCO Annual Meeting and highlight the potential of this combination regimen as a treatment option for mCRC patients.
Gilead Sciences and Arcus Biosciences announced positive results from the Phase 2 EDGE-Gastric study, which evaluated the combination of domvanalimab, zimberelimab, and chemotherapy in treating upper GI cancers. Results showed a median progression-free survival (PFS) of over one year, with a 12-month PFS rate of nearly 60%. The regimen demonstrated consistent objective response rates and was well-tolerated, with no unexpected safety signals. These findings support the ongoing Phase 3 STAR-221 study, which aims to confirm these results and potentially bring the first anti-TIGIT combination therapy to market for upper GI cancers. Data will be presented at the ASCO Annual Meeting.
Gilead Sciences and Arcus Biosciences announced promising results from the Phase 2 EDGE-Gastric study evaluating domvanalimab plus zimberelimab and chemotherapy in treating upper gastrointestinal (GI) cancers. The updated data show a median progression-free survival (PFS) beyond one year, surpassing historical benchmarks for similar treatments. Nearly 60% of patients achieved 12-month PFS. The ongoing Phase 3 STAR-221 study aims to further validate these results. The combination therapy was well-tolerated with a safety profile consistent with the individual components. These outcomes support the potential for this combination to address unmet needs in upper GI cancer treatment.